About: Mapping the Immunodominance Landscape of SARS-CoV-2 Spike Protein for the Design of Vaccines against COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Mapping the Immunodominance Landscape of SARS-CoV-2 Spike Protein for the Design of Vaccines against COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Mapping the Immunodominance Landscape of SARS-CoV-2 Spike Protein for the Design of Vaccines against COVID-19
Creator	Tong, Yi-Gang Huang, Jian-Dong Chan, Kwok-Hung Li, Wenjun Chu, Hin Cai, Jian-Piao To, Kai-Wang Yuen, Chen, Lin-Lei Deng, Jian Dou, Ying Hu, Jing-Chu Hu, Ye-Fan Hung, Fan-Ngai Wang, Xiao-Lei Zhang, Bao-Zhong Chung, Thomas Gong, Hua-Rui Kuwentrai, Chaiyaporn Su, Cai-Hui Yau, Cheung Yung, Kwok
Source	BioRxiv
abstract	The ongoing coronavirus disease 2019 (COVID-19) pandemic is a serious threat to global public health, and imposes severe burdens on the entire human society. The severe acute respiratory syndrome (SARS) coronavirus-2 (SARS-CoV-2) can cause severe respiratory illness and death. Currently, there are no specific antiviral drugs that can treat COVID-19. Several vaccines against SARS-CoV-2 are being actively developed by research groups around the world. The surface S (spike) protein and the highly expressed internal N (nucleocapsid) protein of SARS-CoV-2 are widely considered as promising candidates for vaccines. In order to guide the design of an effective vaccine, we need experimental data on these potential epitope candidates. In this study, we mapped the immunodominant (ID) sites of S protein using sera samples collected from recently discharged COVID-19 patients. The SARS-CoV-2 S protein-specific antibody levels in the sera of recovered COVID-19 patients were strongly correlated with the neutralising antibody titres. We used epitope mapping to determine the landscape of ID sites of S protein, which identified nine linearized B cell ID sites. Four out of the nine ID sites were found in the receptor-binding domain (RBD). Further analysis showed that these ID sites are potential high-affinity SARS-CoV-2 antibody binding sites. Peptides containing two out of the nine sites were tested as vaccine candidates against SARS-CoV-2 in a mouse model. We detected epitope-specific antibodies and SARS-CoV-2-neutralising activity in the immunised mice. This study for the first time provides human serological data for the design of vaccines against COVID-19.
has issue date	2020-04-27(xsd:dateTime)
bibo:doi	10.1101/2020.04.23.056853
has license	biorxiv
sha1sum (hex)	37e61663999bea25aaeb373907925b1d9dba511b
schema:url	https://doi.org/10.1101/2020.04.23.056853
resource representing a document's title	Mapping the Immunodominance Landscape of SARS-CoV-2 Spike Protein for the Design of Vaccines against COVID-19
schema:publication	bioRxiv
resource representing a document's body	covid:37e61663999bea25aaeb373907925b1d9dba511b#body_text
is schema:about of	named entity 'SARS-CoV-2' named entity 'severe acute respiratory syndrome' named entity 'SARS' named entity 'COVID' named entity 'nucleocapsid' named entity 'receptor' named entity 'vaccine' named entity 'Peptides' named entity 'RBD' named entity 'coronavirus' named entity 'vaccines' named entity 'SARS-CoV-2' named entity 'Immunodominance' named entity 'Vaccines' named entity 'worldwide pandemic' named entity 'antigenic' named entity 'high affinity' named entity 'neutralising antibody' named entity 'SARS-CoV-2' named entity 'Immunodominance' named entity 'SARS-CoV' named entity 'antibodies' named entity 'protein' named entity 'epitopes' named entity 'immunodominance' named entity 'immunodominance' named entity 'SARS-CoV' named entity 'epitopes' named entity 'epitopes' named entity 'immunodominance' named entity 'protein' named entity 'COVID-19' named entity 'previously identified' named entity 'SARS-CoV-2' named entity 'epitopes' named entity 'SARS-CoV-2' named entity 'immunisation' named entity 'RBD' named entity 'coronavirus disease 2019' named entity 'protein' named entity 'RBD' named entity 'epitopes' named entity 'correlation' named entity 'epitope' named entity 'antibodies' named entity 'immunogenic' named entity 'vaccines' named entity 'mice' named entity 'subunit vaccines' named entity 'mice' named entity 'influenza' named entity 'RBD' named entity 'adverse reactions' named entity 'histopathological' named entity 'infectious disease' named entity 'immunodominant' named entity 'RBD' named entity 'RBD' named entity 'COVID' named entity 'SARS-CoV' named entity 'vaccines' named entity 'viruses' named entity 'severe acute respiratory syndrome coronavirus 2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software